

Multiplexion Assures Quality of Research Results**Spinout from German Cancer Research Center checks cell cultures for contamination**

Contamination of cell cultures by bacteria, viruses or other cells is a widespread problem in biomedical research. The company Multiplexion, a spinout from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), checks cell cultures of clients from research institutes and companies for many different types of contamination and verifies the identity of cell lines. The test is quick and low-cost and contributes to quality assurance and reproducibility of biomedical research results.

Cancer research, like all other biomedical sciences, relies on them: Living cells, kept in sterile culture dishes in laboratory incubators around the globe, are the chief study objects and outcome providers. However, a common and well-known problem is cell culture contamination by microorganisms or foreign cells. Fifteen to thirty percent of all cell lines are rated as contaminated or – worse even – are not even what the researcher thinks he or she is cultivating. Contamination is also frequently the reason why cell experiments fail to deliver useful and reproducible results. In the worst case, results obtained using contaminated cells will set scientists on the wrong track.

Multiplexion GmbH, a spinout from the German Cancer Research Center (DKFZ), offers scientists quality assurance for their research results. Company founder Dr. Markus Schmitt has developed a testing system for simultaneous detection of 25 different types of contamination – viruses, bacteria and foreign-cell contamination. The test called “Multiplex Cell Contamination Test” detects twelve different mycoplasma types. These bacteria, which are invisible under the microscope, often contaminate cultured cells. Moreover, the test detects a common retrovirus and the genomes of twelve different animal species to provide clues about contamination by foreign cells.

The company also offers a method for verifying cell line identity called “Multiplex Human Cell Line Authentication Test”. The test is based on detection of so-called single-nucleotide polymorphisms (SNPs) and hence avoids error sources which have occurred in other previously used cell identity detection methods.

The testing systems offered by Multiplexion have been tested intensively for many years at DKFZ. Clients – from public research institutes or companies – can send their cell samples, processed according to a simple protocol, by mail and will be notified within just a few business days by e-mail about the test results for their cells.

Contact: Dr. Markus Schmitt
www.multiplexion.de

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg where promising approaches from cancer research are translated into the clinic. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The center is a member of the Helmholtz Association of National Research Centers. Ninety percent of its funding comes from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Dr. Stefanie Seltmann
Head of Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968